7th Advances in Circulating Tumor Cells (ACTC) Meeting: "Liquid Biopsy: from Bench to Bedside"

7th Advances in Circulating Tumor Cells: 'Liquid Biopsy: From Bench to Bedside' (ACTC) is organized by Erasmus Conferences & Events S.A. ,Hellenic Society of Liquid Biopsy (HSLB), Evi Lianidou, University of Athens and will be held from Sep 24 - 27, 2025 at Makedonia Palace Hotel ,Thessaloniki, Central Macedonia, Greece.

Description:
Liquid biopsy has already revealed its tremendous potential to significantly change the therapeutic strategy and management of cancer patients. The 7th ACTC meeting (www.actc2025.org) will focus on the latest advances on liquid biopsy basic research, state of the art technologies, and clinical applications in many types of cancer, from bench to bedside.

They aim to bring together again a critical mass of Key Opinion Leaders in the field, world-top liquid biopsy clinicians and researchers, postgraduate students, and technology providers, So that we will all have again the chance to interact, establish fruitful collaborations and present state of the art data and technology innovations in the field in a highly safe, relaxing and stimulating environment. During intense keynote, oral and poster presentation sessions, mostly unpublished cutting-edge research on the latest achievements, and technical advancements on CTCs, ctDNA and EVs analysis, will be presented. Latest findings on clinical trials based on liquid biopsy will be discussed. Three travel grants and three poster awards will be granted to the best submitted abstracts that will be evaluated by the International Scientific Committee members. More importantly, the 7th ACTC meeting aims to give all participants the chance to establish strong collaborations and networks in a unique, relaxing and stimulating environment.

Main Topics
• Latest Developments on:
  • Circulating Tumor Cells (CTCs)
  • Circulating tumor DNA (ctDNA)
  • Circulating miRNAs (cfmiRNAs)
  • Exosomes and extracellular vesicles (EVs)

• Novel and established technologies in Liquid Biopsies:
  • CTC isolation and detection systems
  • Single-cell drug testing
  • Epigenetic signatures

• Clinical Applications on:
  • Early detection
  • Detection of minimal residual disease
  • Cancer screening for patient selection
  • Monitoring treatment response and drug resistance
  • Liquid biopsy as a treatment-selection tool in advanced cancers
  • Clinical trials

• Implementation in Clinical Practice:
  • Pre-analytical considerations, quality control
  • Standardizing Liquid Biopsy for clinical use
  • International Public-Private Partnerships on liquid biopsy
  • Regulatory Considerations for Utilizing Liquid Biopsies in Drug and Diagnostics Development